D2HGDH and cancer: We conclude that rare somatic D2HGDH mutation is a pervasive event in cancer; as mutation frequency is not an absolute determining factor for their relevance28, we propose that the final determination as to whether D2HGDH variants contribute to cancer initiation and/or progression awaits the generation of relevant mouse models.